Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

176. Adaptimmune Therapeutics plc Announces Closing of $42 Million Register

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering19/04/2017Philadelphia, USA and Oxford, UK: Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately


177. Adaptimmune Therapeutics plc Announces Registered Direct Offering of A

Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares05/04/2017Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its American Depositary Shares (“ADSs”) in a registered direct offering. The t


178. Endo International plc Announces Proposed Private Offering of Senior S

Endo International plc Announces Proposed Private Offering of Senior Secured Notes10/04/2017Endo International plc (NASDAQ: ENDP) ("Endo") today announced that Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (collectively, the "Issuers"), its wholly-owned subsidiaries, intend to offer senior secured notes, subject to market and customary conditions. The notes will be senior obligations of the Issuers and will be guaranteed by Endo and certain of Endo's subsidiaries and wil


179. Adaptimmune Therapeutics plc Announces Closing of $42 Million Register

Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering10/04/2017Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approx


180. Consilium Strategic Communications and Westwicke Partners Enter into J

Consilium Strategic Communications and Westwicke Partners Enter into Joint Venture for Healthcare Focused US IR Advisory10/04/2017Consilium Strategic Communications, a global leader in strategic healthcare communications, today announces a joint venture with Westwicke Partners, the largest independent healthcare-focused investor relations and capital markets advisory firm in the US.Consilium and Westwicke already support a number of shared clients and the new joint venture will see the two teams



Page 36 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019